Follicular Lymphoma (FL)
Conditions
Interventions
Experimental: Golcadomide + Rituximab
Drug: Golcadomide/Specified dose on specified days
Drug: Rituximab/Specified dose on specified days
Active Comparator:
Rituximab + Lenalidomide/Chemothera
Sponsors
Naka Ryosuke
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: - Participant has histologically confirmed FL (Grade 1, 2, 3a or classic FL) as assessed by local pathology. Adequate fresh tumor biopsy tissue or archived tumor biopsy from the latest relapse if available with corresponding pathology report for retrospective central pathology confirmation of relapse, is required. Evaluation from fine needle aspirate is not permitted. - Relapsed or refractory disease: i) Relapsed FL is defined as relapse after an initial response of CR or PR to the most recent prior therapy. ii) Refractory FL is defined as best response of SD or PD or a response that lasted less than 6 months to the most recent prior therapy. - Eastern Cooperative Oncology Group (ECOG) 0-2 (ECOG 3 authorized if it is due to lymphoma and not comorbidities). - Participant must have positron emission tomography (PET)-positive disease with at least one PET-positive lesion and measurable disease on cross section imaging by CT, as defined by Lugano classification. - Participants with an indication for anti-lymphoma treatment as per investigator assessment based on modified Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria. - Participant has received at least 1 or more prior lines of systemic therapy with one line consisting of a combination including an anti-CD20 monoclonal antibody (eg, rituximab, obinutuzumab) and an alkylating agent (eg, cyclophosphamide, bendamustine). Prior treatment with radiation therapy does not count as a line of therapy for eligibility.
Exclusion criteria
Exclusion criteria: - Evidence or history of composite Diffuse large B-cell lymphoma (DLBCL) and FL or of transformed Non-Hodgkin Lymphoma (NHL) or any other indolent lymphoma. - Follicular large cell as per 5th World Health Organization (WHO) sub-classification (grade 3b FL per WHO 4th classification) or duodenal-type FL. - Participant has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the participant from compliantly participating in the study based on Investigator's judgment. - Participant has any condition that confounds the ability to interpret data from the study based on Investigator's or Sponsor's judgment. - Presence or history of central nervous system (CNS) involvement by lymphoma. - History of stroke or intracranial hemorrhage within 6 months prior to enrollment. - Deep venous thrombosis/Pulmonary embolism within 1 month prior to enrollment. - Participants with a history of progressive multifocal leukoencephalopathy. - Participant has any other subtype of lymphoma. - Participant has persistent diarrhea or malabsorption >= Grade 2 (NCI CTCAE v5.0), despite medical management. - History of another primary malignancy that has not been in remission for >= 3 years except for non-invasive malignancies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-Free Survival | — |
Secondary
| Measure | Time frame |
|---|---|
| - Overall Response - Overall Survival - Complete Metabolic Response Rate - Duration of response - Event free survival - Time to next anti-lymphoma treatment - Progression-Free Survival on next anti-lymphoma treatment - Participant-reported FL symptoms, functioning, and health related quality of life - MRD negativity at EOT | — |
Countries
Australia, Brazil, Canada, Chile, China, Finland, France, Germany, Greece, India, Italy, Japan, Netherlands, Poland, Republic of Korea, Saudi Arabia, Spain, Turkey, United Arab Emirates, United Kingdom, United States
Contacts
Public ContactRyosuke Naka
Bristol-Myers Squibb
Outcome results
None listed